BRPI0609702A2 - biomarcadores para a eficácia de aliskiren como um agente hipertensivo - Google Patents
biomarcadores para a eficácia de aliskiren como um agente hipertensivo Download PDFInfo
- Publication number
- BRPI0609702A2 BRPI0609702A2 BRPI0609702-2A BRPI0609702A BRPI0609702A2 BR PI0609702 A2 BRPI0609702 A2 BR PI0609702A2 BR PI0609702 A BRPI0609702 A BR PI0609702A BR PI0609702 A2 BRPI0609702 A2 BR PI0609702A2
- Authority
- BR
- Brazil
- Prior art keywords
- gene
- individual
- aliskiren
- snp
- treatment
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 239000002220 antihypertensive agent Substances 0.000 claims 15
- 229940030600 antihypertensive agent Drugs 0.000 claims 15
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 14
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 14
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 13
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 108050008993 Angiotensin II receptor type 2 Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 102000000469 Angiotensin II receptor type 2 Human genes 0.000 claims 9
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 8
- 229960004601 aliskiren Drugs 0.000 claims 8
- 230000002068 genetic effect Effects 0.000 claims 8
- 206010020772 Hypertension Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010071602 Genetic polymorphism Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 101710101155 Type-2 angiotensin II receptor Proteins 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 claims 2
- 230000035487 diastolic blood pressure Effects 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 101150116411 AGTR2 gene Proteins 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66424805P | 2005-03-22 | 2005-03-22 | |
| US60/664,248 | 2005-03-22 | ||
| US74240106P | 2006-02-06 | 2006-02-06 | |
| US60/742,401 | 2006-02-06 | ||
| PCT/US2006/009913 WO2006102177A2 (en) | 2005-03-22 | 2006-03-20 | Biomarkers for efficacy of aliskiren as a hypertensive agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0609702A2 true BRPI0609702A2 (pt) | 2010-04-20 |
Family
ID=37024459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0609702-2A BRPI0609702A2 (pt) | 2005-03-22 | 2006-03-20 | biomarcadores para a eficácia de aliskiren como um agente hipertensivo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100240760A1 (enExample) |
| JP (1) | JP2008538549A (enExample) |
| KR (1) | KR20080005926A (enExample) |
| AU (1) | AU2006227283B2 (enExample) |
| BR (1) | BRPI0609702A2 (enExample) |
| CA (1) | CA2600525A1 (enExample) |
| MX (1) | MX2007011697A (enExample) |
| WO (1) | WO2006102177A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0609702A2 (pt) * | 2005-03-22 | 2010-04-20 | Novartis Ag | biomarcadores para a eficácia de aliskiren como um agente hipertensivo |
| PT2205279E (pt) * | 2007-09-28 | 2011-07-11 | Novartis Ag | Associação farmacêutica de aliscireno e valsartan |
| CN108660205A (zh) * | 2018-07-04 | 2018-10-16 | 刘城 | 一种糖尿病遗传风险评估试剂盒及其运用 |
| CN111024960B (zh) * | 2019-12-27 | 2023-02-17 | 广州阳普医疗科技股份有限公司 | 用于高血压血样检测的添加剂、试剂盒和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988008457A1 (en) * | 1987-04-30 | 1988-11-03 | Biotechnology Research Partners, Ltd. | Hypertension-related blood tests useful as genetic markers |
| WO2000022166A2 (en) * | 1998-10-14 | 2000-04-20 | Pyrosequencing Ab | Genes for assessing cardiovascular status and compositions for use thereof |
| PL219032B1 (pl) * | 2002-05-17 | 2015-03-31 | Novartis Ag | Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację |
| US8304190B2 (en) * | 2005-02-02 | 2012-11-06 | Royal College Of Surgeons In Ireland | Pharmacogenomics of blood pressure lowering agents |
| BRPI0609702A2 (pt) * | 2005-03-22 | 2010-04-20 | Novartis Ag | biomarcadores para a eficácia de aliskiren como um agente hipertensivo |
-
2006
- 2006-03-20 BR BRPI0609702-2A patent/BRPI0609702A2/pt not_active IP Right Cessation
- 2006-03-20 JP JP2008503059A patent/JP2008538549A/ja active Pending
- 2006-03-20 CA CA002600525A patent/CA2600525A1/en not_active Abandoned
- 2006-03-20 US US11/909,202 patent/US20100240760A1/en not_active Abandoned
- 2006-03-20 AU AU2006227283A patent/AU2006227283B2/en not_active Ceased
- 2006-03-20 WO PCT/US2006/009913 patent/WO2006102177A2/en not_active Ceased
- 2006-03-20 KR KR1020077024124A patent/KR20080005926A/ko not_active Ceased
- 2006-03-20 MX MX2007011697A patent/MX2007011697A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006227283B2 (en) | 2010-07-01 |
| WO2006102177A2 (en) | 2006-09-28 |
| US20100240760A1 (en) | 2010-09-23 |
| JP2008538549A (ja) | 2008-10-30 |
| MX2007011697A (es) | 2007-11-16 |
| WO2006102177A3 (en) | 2007-05-10 |
| KR20080005926A (ko) | 2008-01-15 |
| CA2600525A1 (en) | 2006-09-28 |
| AU2006227283A1 (en) | 2006-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100035251A1 (en) | BioMarkers for the Progression of Alzheimer's Disease | |
| US20100249107A1 (en) | Biomarkers for Alzheimer's Disease Progression | |
| US20070065821A1 (en) | Methods for the prediction of suicidality during treatment | |
| WO2006104812A2 (en) | Biomarkers for pharmacogenetic diagnosis of type 2 diabetes | |
| US20090118350A1 (en) | Biomarkers for Identifying Efficacy of Tegaserod in Patients with Chronic Constipation | |
| WO2006060429A2 (en) | Identification of variants in histone deacetylase 1 (hdac1) to predict drug response | |
| BRPI0609702A2 (pt) | biomarcadores para a eficácia de aliskiren como um agente hipertensivo | |
| WO2007022041A2 (en) | Mutations and polymorphisms of hdac3 | |
| RU2408363C2 (ru) | Биомаркеры для оценки эффективности алискирена в качестве гипертензивного агента | |
| JP4979382B2 (ja) | 薬剤誘発肝細胞毒性を予測するための遺伝子多型の使用 | |
| CN1973051A (zh) | 用于预测对氯氮平治疗的应答性的生物标记 | |
| WO2007058992A2 (en) | Mutations and polymorphisms of hdac6 | |
| WO2007109183A2 (en) | Mutations and polymorphisms of fms-related tyrosine kinase 1 | |
| WO2007030455A2 (en) | Mutations and polymorphisms of hdac10 | |
| WO2007002217A2 (en) | Mutations and polymorphisms of bcl-2 | |
| WO2007047998A2 (en) | Mutations and polymorphisms of hdac2 | |
| WO2007053502A2 (en) | Mutations and polymorphisms of hdac5 | |
| WO2007058991A2 (en) | Mutations and polymorphisms of c-abl | |
| CN101146915A (zh) | 高血压药阿利克仑功效的生物标志物 | |
| WO2007121017A2 (en) | Mutations and polymorphisms of fms-like tyrosine kinase 4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |